These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31402591)

  • 21. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
    Long EF; Stavert RR
    J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cost-effectiveness analysis for HIV pre-exposure prophylaxis in a high-risk population in the Czech Republic].
    Skoupá J; Švecová K; Snopková S
    Klin Mikrobiol Infekc Lek; 2020 Mar; 26(1):18-24. PubMed ID: 33326591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Pre-Exposure Prophylaxis Among Adolescent Sexual Minority Males.
    Wang LY; Hamilton DT; Rosenberg ES; Aslam MV; Sullivan PS; Katz DA; Dunville RL; Barrios LC; Goodreau SM
    J Adolesc Health; 2020 Jan; 66(1):100-106. PubMed ID: 31757626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
    AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
    Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
    J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis.
    Cambiano V; Miners A; Lampe FC; McCormack S; Gill ON; Hart G; Fenton KA; Cairns G; Thompson M; Delpech V; Rodger AJ; Phillips AN
    Lancet HIV; 2023 Nov; 10(11):e713-e722. PubMed ID: 37923485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of a Statewide Pre-Exposure Prophylaxis Program for Gay, Bisexual, and Other Men Who Have Sex with Men.
    Goedel WC; Chan PA; King MRF; Prosperi MCF; Marshall BDL; Galárraga O
    R I Med J (2013); 2019 Nov; 102(9):36-39. PubMed ID: 31675786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
    Amick AK; Eskibozkurt GE; Hosek SG; Flanagan CF; Landovitz RJ; Jin EY; Wilson CM; Freedberg KA; Weinstein MC; Kazemian P; Paltiel AD; Ciaranello AL; Neilan AM
    Clin Infect Dis; 2024 Feb; 78(2):402-410. PubMed ID: 37823865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential Impact of Targeted HIV Pre-Exposure Prophylaxis Uptake Among Male Sex Workers.
    Goedel WC; Mimiaga MJ; King MRF; Safren SA; Mayer KH; Chan PA; Marshall BDL; Biello KB
    Sci Rep; 2020 Mar; 10(1):5650. PubMed ID: 32221469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease.
    Kazemian P; Costantini S; Neilan AM; Resch SC; Walensky RP; Weinstein MC; Freedberg KA
    J Biomed Inform; 2020 Jul; 107():103475. PubMed ID: 32526280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
    Kazemian P; Costantini S; Kumarasamy N; Paltiel AD; Mayer KH; Chandhiok N; Walensky RP; Freedberg KA
    Clin Infect Dis; 2020 Feb; 70(4):633-642. PubMed ID: 30921454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
    Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB
    PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Interventions to Improve HIV Pre-exposure Prophylaxis Initiation, Adherence, and Persistence Among Men Who Have Sex With Men.
    Wheatley MM; Knowlton G; Kao SY; Jenness SM; Enns EA
    J Acquir Immune Defic Syndr; 2022 May; 90(1):41-49. PubMed ID: 35090155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
    Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
    Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men.
    McKenney J; Chen A; Hoover KW; Kelly J; Dowdy D; Sharifi P; Sullivan PS; Rosenberg ES
    PLoS One; 2017; 12(6):e0178170. PubMed ID: 28570572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
    J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.